Ken Griffin Catalent, Inc. Transaction History

Citadel Advisors LLC

$483 Billion
Q2 2024

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Catalent, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 41,800 shares of CTLT stock, worth $2.47 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

41,800

Previous 41,300 1.21%

Holding current value

$2.47 Million

Previous $2.33 Million 0.82%

% of portfolio

0.0%

Previous 0.0%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$53.58 - $57.02 $81.7 Million - $86.9 Million	1,524,680 Added 347.91%	1,962,923 $110 Million
Q1 2024 May 15, 2024	SELL	$42.56 - $59.82 $58.6 Million - $82.4 Million	-1,377,555 Reduced 75.86%	438,243 $24.7 Million
Q4 2023 Feb 14, 2024	BUY	$32.18 - $46.57 $49.3 Million - $71.3 Million	1,532,069 Added 539.98%	1,815,798 $81.6 Million
Q3 2023 Nov 14, 2023	BUY	$44.2 - $50.2 $2.97 Million - $3.37 Million	67,202 Added 31.04%	283,729 $12.9 Million
Q2 2023 Aug 14, 2023	SELL	$31.86 - $67.26 $9.13 Million - $19.3 Million	-286,503 Reduced 56.96%	216,527 $9.39 Million
Q1 2023 May 15, 2023	BUY	$45.44 - $74.26 $17.6 Million - $28.8 Million	387,836 Added 336.68%	503,030 $33.1 Million
Q4 2022 Feb 14, 2023	BUY	$41.39 - $81.0 $3.05 Million - $5.97 Million	73,765 Added 178.05%	115,194 $5.18 Million
Q3 2022 Nov 14, 2022	SELL	$72.36 - $113.1 $578,662 - $904,460	-7,997 Reduced 16.18%	41,429 $3 Million
Q2 2022 Aug 15, 2022	BUY	$87.2 - $114.05 $2.81 Million - $3.67 Million	32,183 Added 186.64%	49,426 $5.3 Million
Q1 2022 May 16, 2022	SELL	$94.19 - $124.49 $7.23 Million - $9.56 Million	-76,811 Reduced 81.67%	17,243 $1.91 Million
Q4 2021 Feb 14, 2022	SELL	$119.57 - $139.07 $58.7 Million - $68.3 Million	-490,881 Reduced 83.92%	94,054 $12 Million
Q3 2021 Nov 15, 2021	SELL	$109.17 - $142.35 $97.4 Million - $127 Million	-891,988 Reduced 60.4%	584,935 $77.8 Million
Q2 2021 Aug 16, 2021	SELL	$100.34 - $115.69 $10.9 Million - $12.6 Million	-108,498 Reduced 6.84%	1,476,923 $160 Million
Q1 2021 May 17, 2021	BUY	$101.51 - $125.27 $137 Million - $169 Million	1,349,520 Added 572.07%	1,585,421 $167 Million
Q4 2020 Feb 16, 2021	SELL	$85.88 - $105.36 $6.26 Million - $7.68 Million	-72,919 Reduced 23.61%	235,901 $24.6 Million
Q3 2020 Nov 16, 2020	BUY	$72.74 - $92.5 $21.1 Million - $26.8 Million	289,544 Added 1502.1%	308,820 $26.5 Million
Q2 2020 Aug 14, 2020	SELL	$48.02 - $79.04 $83.9 Million - $138 Million	-1,747,280 Reduced 98.91%	19,276 $1.41 Million
Q1 2020 May 15, 2020	BUY	$36.95 - $62.95 $20.2 Million - $34.4 Million	546,634 Added 44.81%	1,766,556 $91.8 Million
Q4 2019 Feb 14, 2020	SELL	$47.06 - $56.64 $4.88 Million - $5.87 Million	-103,676 Reduced 7.83%	1,219,922 $68.7 Million
Q3 2019 Nov 14, 2019	SELL	$47.45 - $58.05 $16.6 Million - $20.3 Million	-348,941 Reduced 20.86%	1,323,598 $63.1 Million
Q2 2019 Aug 14, 2019	BUY	$39.26 - $54.21 $24.3 Million - $33.6 Million	619,847 Added 58.88%	1,672,539 $90.7 Million
Q1 2019 May 15, 2019	SELL	$29.84 - $43.92 $4.6 Million - $6.77 Million	-154,239 Reduced 12.78%	1,052,692 $0
Q4 2018 Feb 14, 2019	BUY	$29.95 - $46.34 $397,586 - $615,163	13,275 Added 1.11%	1,206,931 $37.6 Million
Q3 2018 Nov 13, 2018	SELL	$40.12 - $45.55 $27.2 Million - $30.9 Million	-677,672 Reduced 36.21%	1,193,656 $0
Q2 2018 Aug 10, 2018	BUY	$38.72 - $42.52 $2.89 Million - $3.17 Million	74,540 Added 4.15%	1,871,328 $0
Q1 2018 May 11, 2018	BUY	$39.4 - $47.39 $15.4 Million - $18.5 Million	390,004 Added 27.72%	1,796,788 $73.8 Million
Q4 2017 Feb 09, 2018	BUY	$37.27 - $43.02 $31.9 Million - $36.8 Million	854,829 Added 154.87%	1,406,784 $57.8 Million
Q3 2017 Nov 09, 2017	BUY	$33.75 - $41.67 $18.6 Million - $23 Million	551,955	551,955 $22 Million

Others Institutions Holding CTLT

# of Institutions

496

Shares Held

163M

Call Options Held

286K

Put Options Held

1.04M

View Full List

About Catalent, Inc.

Ticker CTLT
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 179,896,000
Market Cap $10.6B
Description
Catalent, Inc., together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. The Softgel and Oral Technologies segment provides formulation, development, and manufacturing services for soft capsules for use in a range of customer products,...

More about CTLT

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account